ARTIFICIAL PANCREAS

New Breakthrough T1D-Funded Technology in Collaboration with BD and Helmsley Charitable Trust Offer Improved Insulin Delivery with Less Pain

Today we celebrate a significant achievement in the fight against T1D. Becton Dickinson Medical announced that the U.S. Food and Drug Administration approved its application to begin production of its novel FlowSmartTM insulin infusion set. This important accomplishment would not have been possible without help from our many supporters. We are extremely grateful to our donors, partners and the entire T1D community.
The new infusion set is designed for use with insulin pumps sold in the U.S., and studies show that it has significantly fewer flow interruptions and blockages than regular sets. The smaller needle also causes less insertion site trauma.

Infusion sets are a critical part of effective insulin-pump therapy, yet these sets have seen little innovation over the years. More than six years ago, Breakthrough T1D Research and BD Diabetes Care leadership helped bridge that gap through a multi-year partnership with BD and a seven-figure investment by Breakthrough T1D and the Helmsley Charitable Trust to develop FlowSmart technology.

This new infusion technology could play an important role in developing highly reliable and effective artificial pancreas systems, which aim to require little monitoring and action on the part of the user. Breakthrough T1D donors helped make possible this important step towards creating a world without T1D.